

PRESS RELEASE

BioVersys AG further strengthens management team with an experienced CSO

Basel, 28th September 2015

BioVersys today announced the appointment of Dr. Sergio Lociuero as new Chief Scientific Officer.

Sergio Lociuero is an experienced scientific leader in the area of antibacterial research, who brings a distinguished track record of nearly 30 years in the field of antibacterial drug discovery to BioVersys.

Prior to joining BioVersys, Sergio held positions such as Director of Chemistry and international Project Leader at GlaxoSmithKline, Head of Peptide Epitope Mimetics in Polyphor Ltd and Head of Research and Scientific Communication in Arpida AG, where he also served on the Board of Directors of Arpida A/S. Most recently he held CSO positions at Adenium Biotech in Copenhagen and C10 Pharma in Oslo. Sergio's experience spans primarily from early drug discovery to late preclinical development and first in man studies. He has also participated in late stage clinical studies and in discussions with both the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Sergio succeeds Dr. Marcel Tigges who left the company for personal reasons. The Board and the Management would like to take the opportunity to thank Marcel Tigges for his efforts and dedication that he put into the creation of the company and wish him all the best for his future undertakings.

"We are delighted to have attracted an experienced professional like Sergio to take up the position of CSO in BioVersys. His proven leadership and experience complements the management team and will play a significant role in the next phase of the company's development" says Dr. Marc Gitzinger, CEO and co-founder of BioVersys.

"The addition of Sergio to the BioVersys team is part of our ongoing efforts to ensure that the right skills sets are in place to address the needs of each stage of the company's development" stated Dr. Seng Chin Mah, Chairman of the Board of Directors of BioVersys.

"I am excited to join BioVersys, a multi-award winning company that really follows new approaches to overcome the serious threat of ever increasing bacterial resistance against antibiotics. I am looking forward to bringing my experience in antibacterial Research and Development to BioVersys and becoming part of this success story" says Dr. Sergio Lociuero.

Contact: Dr. Marc Gitzinger, CEO, Tel. +41 61 633 2250, marc.gitzinger@bioversys.com

BioVersys AG is a privately held biopharmaceuticals company. It is a spin-off company from the ETH Zurich located in Basel. The company focuses on the research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and thus restore the efficacy of existing antibiotics. The current research focus is Nosocomial Infections (hospital infections) and Tuberculosis. In collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, BioVersys is developing a preclinical candidate against tuberculosis. The Team and the technology of BioVersys have already received multiple awards, such as Venture Kick, the Heuberger Winterthur Jungunternehmerpreis 2009, the Swiss TB Award, the Life Sciences Prize 2011, the Swiss Technology Award 2011 and the Jungunternehmerpreis Nordwestschweiz 2012. (www.bioversys.com)